Mechanism-based inactivation of human recombinant P4502C9 by the nonsteroidal anti-inflammatory drug suprofen

被引:61
|
作者
O'Donnell, JP [1 ]
Dalvie, DK [1 ]
Kalgutkar, AS [1 ]
Obach, RS [1 ]
机构
[1] Pfizer Global Res & Dev, Pharmacokinet Dynam & Metab Dept, Groton, CT 06340 USA
关键词
D O I
10.1124/dmd.31.11.1369
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The nonsteroidal anti-inflammatory agent (+/-)-suprofen [alpha-methyl-4-( 2-thienylcarbonyl) benzeneacetic acid] was evaluated as a P450 2C9 inactivator. (+/-)-Suprofen inactivated the diclofenac-4-hydroxylase activity of baculovirus-expressed P450 2C9 in a time- and concentration-dependent manner, which was consistent with mechanism-based inactivation. The loss of activity followed pseudo-first-order kinetics and was suprofen- and NADPH-dependent. The kinetic parameters for inactivation k(inact) and K-I were 0.091 min(-1) and 3.7 muM, respectively, and the partition ratio was 101. Although P450 2C9 substrate S-warfarin partially protected against inactivation, reactive oxygen scavengers such as superoxide dismutase and catalase did not prevent inactivation. Extensive dialysis did not regenerate enzyme activity, suggesting that inactivation proceeded via covalent modification. Inactivated P450 2C9 lost < 10% of its ability to form a CO-reduced complex, suggesting that inactivation may have resulted from covalent modification of apoprotein. Addition of exogenous nucleophiles such as glutathione and semicarbazide partially protected against inactivation. Apart from the metabolism of suprofen to 5-hydroxysuprofen, the formation of a suprofen-glutathione conjugate was also discernible in microsomal mixtures containing glutathione. Time of flight mass spectrometry revealed a protonated monoisotopic mass of 566.1304 for this conjugate, consistent with an elemental composition of C24H28N3O9S2. The mass spectrum indicated that conjugation had occurred on the intact thiophene ring, presumably via a thioether linkage. Further evidence for the formation of an electrophilic intermediate in suprofen-P450 2C9 incubations was obtained via the characterization of a novel pyridazine adduct upon addition of semicarbazide to the microsomal mixtures. The pyridazine derivative had a protonated monoisotopic mass of 257.0895 that was consistent with an elemental composition of C14H13O3N2. The formation of the stable pyridazine adduct suggested the generation of an electrophilic γ-thioketo-α,β-unsaturated aldehyde, analogous to that observed during the cytochrome P450-mediated bioactivation of furan. This electrophilic α,β-unsaturated aldehyde represents a possible reactive intermediate that bioalkylates P450 2C9.
引用
收藏
页码:1369 / 1377
页数:9
相关论文
共 50 条
  • [1] Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: Role of cytochrome P4502C9 polymorphisms
    Pilotto, Alberto
    Seripa, Davide
    Franceschi, Marilisa
    Scarcelli, Carlo
    Colaizzo, Donatella
    Grandone, Elvira
    Niro, Valeria
    Andriulli, Angelo
    Leandro, Gioacchino
    Di Mario, Francesco
    Dallapiccola, Bruno
    [J]. GASTROENTEROLOGY, 2007, 133 (02) : 465 - 471
  • [2] Allelic variants of cytochrome P4502C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants
    Visser, LE
    van Schaik, RHN
    van Vliet, M
    Trienekens, PH
    De Smet, PAGM
    Vulto, AG
    Hofman, A
    van Duijn, CM
    Stricker, BHC
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (06) : 479 - 485
  • [3] Crystallization of human P4502C9
    Wester, MR
    Stout, CD
    Schoch, G
    Yano, JK
    Johnson, EF
    [J]. FASEB JOURNAL, 2003, 17 (04): : A609 - A609
  • [4] Substrate selectivity of human cytochrome P4502C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid
    Melet, A
    Assrir, N
    Jean, P
    Lopez-Garcia, MP
    Marques-Soares, C
    Jaouen, M
    Dansette, PM
    Sari, MA
    Mansuy, D
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 409 (01) : 80 - 91
  • [5] Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro
    Polasek, TM
    Elliot, DJ
    Lewis, BC
    Miners, JO
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (03): : 996 - 1007
  • [6] Cytochrome P4502C9: an enzyme of major importance in human drug metabolism
    Miners, JO
    Birkett, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) : 525 - 538
  • [7] Mechanism-based inactivation of recombinant and human liver microsomal cytochrome P4502C8 (CYP2C8)
    Polasek, TM
    Elliot, DJ
    Miners, JO
    [J]. DRUG METABOLISM REVIEWS, 2004, 36 : 271 - 271
  • [8] Study of recombinant cytochrome P4502C9 activity with diclofenac by MEKC
    Konecny, Jiri
    Jurica, Jan
    Tomandl, Josef
    Glatz, Zdenek
    [J]. ELECTROPHORESIS, 2007, 28 (08) : 1229 - 1234
  • [9] The mechanism-based inactivation of human cytochrome P4502B6 by phencyclidine
    Jushchyshyn, MI
    Kent, UM
    Hollenberg, PF
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) : 46 - 52
  • [10] Gemfibrozil is a potent inhibitor of human cytochrome P4502C9
    Wen, X
    Wang, JS
    Backman, JT
    Kivistö, KT
    Neuvonen, PJ
    [J]. DRUG METABOLISM AND DISPOSITION, 2001, 29 (11) : 1359 - 1361